RBX-6610 / Ribometrix - LARVOL DELTA

eIF4E inhibition exhibits anti-tumor activity and re-sensitizes acquired resistant KRAS G12C NSCLC to KRAS inhibitors (ESMO 2024) - "Background: The approval of KRASG12C selective inhibitors, sotorasib and adagrasib, marked a critical point in the effort to treat KRASG12C mutant NSCLC. Collectively, these data support the addition of RBX-6610 to standard of care in both the naïve and treatment resistance settings in KRASmut NSCLC patients. IND-enabling studies are planned, marking a significant step toward advancing RBX-6610, a potent eIF4E inhibitor, into the clinic."

IO biomarker • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • BCL2 • CASP3 • CASP7 • CCND1 • EIF4A1 • EIF4A2 • EIF4E • KRAS • MCL1

Ribometrix Present Data Supporting Potential of eIF4E Program in KRAS Mutant Non-Small Cell Lung Cancer at ESMO 2024 (Businesswire) - "Ribometrix, a biotechnology company developing small molecule therapeutics that modulate RNA biology, presented the latest data from its eIF4E program at the European Society for Medical Oncology (ESMO) Congress, taking place in Barcelona, Spain, September 13-17....RBX-6610 demonstrated consistent anti-proliferative effects in KRASG12C mutant tumor cell lines, in both treatment-naïve lines and those with acquired resistance. Additionally, the combined in vitro effects of co-treatment of RBX-6610 with KRAS inhibitors were synergistic, such that the proliferative inhibitory effects were greater than the sum of either treatment alone....Daily oral RBX-6610 monotherapy led to substantial tumor growth inhibition in both treatment naïve and resistant KRASG12C NSCLC xenograft model (75% vs 71% TGI, respectively), corroborating the anti-proliferative effects seen in vitro."

Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Ribometrix To Present Data Supporting Potential of eIF4E Program in KRAS Mutant Non-Small Cell Lung Cancer at ESMO 2024 (Businesswire) - "A poster presentation will review in vitro and in vivo studies of a small molecule eIF4E inhibitor, RBX-6610, as a potential treatment for non-small cell lung cancer (NSCLC), specifically NSCLC with KRASG12C, a common mutation...In vitro outcomes in the poster include: RBX-6610 monotherapy demonstrated consistent anti-proliferative effects in KRASG12C mutant tumor cell lines, in both treatment-naïve lines and those with acquired resistance; RBX-6610 combined with KRAS inhibitors resulted in a synergistic apoptotic induction in treatment-naïve tumor cells and re-sensitized resistant tumor cells to KRAS inhibitors. In vivo outcomes in the poster include: RBX-6610 monotherapy caused significant tumor growth inhibition; RBX-6610 combined with a KRAS inhibitor resulted in significant tumor regression in a treatment-naïve model; A further in vivo study reviewing RBX-6610’s ability to re-sensitize tumor cells to KRAS inhibition will be included in the final poster presentation."

Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Ribometrix Presents First c-MYC Data Validating RNA-Targeting Platform and Demonstrates Synergistic Potential of eIF4E Program at AACR 2024 (Businesswire) - "The data in the second poster demonstrate how Ribometrix: Synergistically enhanced in vivo anti-tumor efficacy of SOC though combination with its eIF4E inhibitor across many tumor types including non-small cell lung cancer, breast cancer, and melanoma. Caused tumor regression in mouse models of aggressive melanoma, ER+ breast cancer and non-small cell lung cancers through combination treatment with SOC. Restored sensitivity to SOC in multiple resistant cell lines in vitro through combination with its eIF4E inhibitor, providing a potential mechanism for re-sensitizing resistant patient populations to initial lines of treatment....We are making excellent progress towards our goal of filing an IND in the first half of 2025."

IND • Preclinical • Breast Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Ribometrix to Present New Preclinical Data From RNA-Modulating Small Molecule Programs Targeting eIF4E and c-MYC at the 2024 AACR Annual Meeting (Businesswire) - "Ribometrix...announced it will present two posters with preclinical data highlighting advancements across two distinct modalities at the 2024 American Association for Cancer Research (AACR) Annual Meeting. The posters will show in vivo anti-tumor efficacy of Ribometrix’s lead candidate targeting the RNA-binding protein eIF4E in combination with standard-of-care across multiple indications, and the Company’s discovery of small molecules that directly bind a complex RNA structure within the c-MYC mRNA in cells, and demonstrate a reduction in c-MYC protein levels."

Preclinical • Oncology

Ribometrix Demonstrates Rapid Progress for eIF4E Program at San Antonio Breast Cancer Symposium (Businesswire) - "Ribometrix...presented preclinical data supporting the potential of its eIF4E inhibitors in Estrogen Receptor-positive (ER+) breast cancer at the annual San Antonio Breast Cancer Symposium (SABCS)....Ribometrix expects to present additional data and select a development candidate in 2024....Daily oral dosing of single agent Ribometrix eIF4E inhibitors shows anti-tumor efficacy in vivo with no signs of overt toxicity in an ER+ breast cancer tumor model....eIF4E inhibition with Ribometrix compounds potentiates cancer cell sensitivity to CDK4/6 inhibition, supporting a combination approach to improve SoC response durability in ER+ breast cancer."

Preclinical • Estrogen Receptor Positive Breast Cancer

Ribometrix to Present Additional Preclinical Data for eIF4E Program at the San Antonio Breast Cancer Symposium (Businesswire) - "Ribometrix...announced it will present preclinical data showing anti-tumor benefit of eIF4E inhibition in Estrogen Receptor-positive (ER+) breast cancer at the annual San Antonio Breast Cancer Symposium, held December 5-9, 2023, in San Antonio, TX....eIF4E is both a potent oncogene and a regulator of resistance to therapies targeting common oncogenic drivers....Data support potential for the company’s eIF4E small molecule inhibitors in treatment naïve and treatment resistant Estrogen Receptor-positive breast cancer."

Preclinical • Estrogen Receptor Positive Breast Cancer

Ribometrix Announces Lead Program Target and Presentation of Preclinical Data at the International Congress of the Society for Melanoma Research (Businesswire) - "Ribometrix...disclosed its lead wholly-owned development program targeting the protein eIF4E, and announced it will present initial preclinical data demonstrating the anti-tumor benefit of eIF4E inhibition at the 20th International Congress of the Society for Melanoma Research (SMR), held November 6-9, 2023, in Philadelphia, PA....Reduce the production of eIF4E-regulated oncoproteins and inhibit the growth of several cancer cell lines, including BRAF mutant melanoma. Demonstrate strong anti-tumor monotherapy efficacy in a xenograft mouse model with no overt signs of toxicity after daily oral dosing. Potentiate the effects of BRAF and MEK inhibitors (BRAFi/MEKi) in treatment naïve BRAF mutant melanoma cell lines."

New molecule • Preclinical • Melanoma • Oncology • Skin Cancer • Solid Tumor